Investment Crackdown Prompts Chinese Investors to Leave U.S. Biotech Market and Focus on Europe

Confusion among Chinese investors about shifting U.S. regulatory policy is draining billions of dollars from the American biotechnology sector and stressing startups that rely on foreign capital to cure disease.
That was the message of James Huang, a managing partner in Kleiner Perkins’s China office who specializes in facilitating cross-border deal financing. He told attendees at the BIO Investment Forum that the Trump administration’s new rules scrutinizing foreign investment